Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 57 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

16%

8 of 49 completed trials have results

Key Signals

2 recruiting8 with results

Enrollment Performance

Analytics

Phase 1
55(96.5%)
Early Phase 1
1(1.8%)
N/A
1(1.8%)
57Total
Phase 1(55)
Early Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials
NCT06558643Phase 1Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Role: collaborator

NCT07518459Phase 1Active Not Recruiting

A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144

Role: collaborator

NCT07453784Phase 1Not Yet Recruiting

Phase 1 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Role: collaborator

NCT06500793Phase 1Recruiting

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Role: collaborator

NCT06144684Phase 1Completed

A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

Role: collaborator

NCT07220954Phase 1Not Yet Recruiting

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Role: collaborator

NCT05294458Phase 1Completed

A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

Role: collaborator

NCT07011511Phase 1Recruiting

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Role: collaborator

NCT06989983Phase 1Completed

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

Role: collaborator

NCT05817461Phase 1Completed

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Role: collaborator

NCT06857695Phase 1Completed

A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

Role: collaborator

NCT05413668Phase 1Completed

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

Role: collaborator

NCT05507970Phase 1Completed

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Role: collaborator

NCT06543043Phase 1Completed

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Role: collaborator

NCT05090280Phase 1Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

Role: collaborator

NCT05364255Phase 1Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Role: collaborator

NCT06157255Phase 1Completed

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Role: collaborator

NCT05012670Phase 1Completed

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Role: collaborator

NCT03437265Phase 1Completed

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Role: collaborator

NCT06028321Phase 1Completed

Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Role: collaborator